PMID- 29743988
OWN - NLM
STAT- MEDLINE
DCOM- 20181022
LR  - 20181114
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2018
DP  - 2018
TI  - Molecular Mechanisms Underlying Curcumin-Mediated Therapeutic Effects in Type 2 
      Diabetes and Cancer.
PG  - 9698258
LID - 10.1155/2018/9698258 [doi]
LID - 9698258
AB  - The growing prevalence of age-related diseases, especially type 2 diabetes 
      mellitus (T2DM) and cancer, has become global health and economic problems. Due 
      to multifactorial nature of both diseases, their pathophysiology is not 
      completely understood so far. Compelling evidence indicates that increased 
      oxidative stress, resulting from an imbalance between production of reactive 
      oxygen species (ROS) and their clearance by antioxidant defense mechanisms, as 
      well as the proinflammatory state contributes to the development and progression 
      of the diseases. Curcumin (CUR; diferuloylmethane), a well-known polyphenol 
      derived from the rhizomes of turmeric Curcuma longa, has attracted a great deal 
      of attention as a natural compound with beneficial antidiabetic and anticancer 
      properties, partly due to its antioxidative and anti-inflammatory actions. 
      Although this polyphenolic compound is increasingly being recognized for its 
      growing number of protective health effects, the precise molecular mechanisms 
      through which it reduces diabetes- and cancer-related pathological events have 
      not been fully unraveled. Hence, CUR is the subject of intensive research in the 
      fields Diabetology and Oncology as a potential candidate in the treatment of both 
      T2DM and cancer, particularly since current therapeutic options for their 
      treatment are not satisfactory in clinics. In this review, we summarize the 
      recent progress made on the molecular targets and pathways involved in 
      antidiabetic and anticancer activities of CUR that are responsible for its 
      beneficial health effects.
FAU - Wojcik, Marzena
AU  - Wojcik M
AUID- ORCID: 0000-0001-5563-8122
AD  - Department of Structural Biology, Faculty of Biomedical Sciences and Postgraduate 
      Education, Medical University of Lodz, ul. Zeligowskiego 7/9, 90-752 Lodz, 
      Poland.
FAU - Krawczyk, Michal
AU  - Krawczyk M
AD  - Department of Structural Biology, Faculty of Biomedical Sciences and Postgraduate 
      Education, Medical University of Lodz, ul. Zeligowskiego 7/9, 90-752 Lodz, 
      Poland.
FAU - Wojcik, Pawel
AU  - Wojcik P
AD  - Department of Horticultural Crop Management and Nutrition, Research Institute of 
      Horticulture, ul. Konstytucji 3 Maja 1/3, 96-100 Skierniewice, Poland.
FAU - Cypryk, Katarzyna
AU  - Cypryk K
AD  - Diabetology and Metabolic Diseases Department, Medical University of Lodz, ul. 
      Pomorska 251, 92-213 Lodz, Poland.
FAU - Wozniak, Lucyna Alicja
AU  - Wozniak LA
AUID- ORCID: 0000-0002-9966-1807
AD  - Department of Structural Biology, Faculty of Biomedical Sciences and Postgraduate 
      Education, Medical University of Lodz, ul. Zeligowskiego 7/9, 90-752 Lodz, 
      Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180320
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Hypoglycemic Agents)
RN  - IT942ZTH98 (Curcumin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antioxidants/*therapeutic use
MH  - Curcuma/immunology
MH  - Curcumin/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Immunomodulation
MH  - Neoplasms/*drug therapy
PMC - PMC5884026
EDAT- 2018/05/11 06:00
MHDA- 2018/10/23 06:00
PMCR- 2018/03/20
CRDT- 2018/05/11 06:00
PHST- 2017/12/22 00:00 [received]
PHST- 2018/02/12 00:00 [revised]
PHST- 2018/02/15 00:00 [accepted]
PHST- 2018/05/11 06:00 [entrez]
PHST- 2018/05/11 06:00 [pubmed]
PHST- 2018/10/23 06:00 [medline]
PHST- 2018/03/20 00:00 [pmc-release]
AID - 10.1155/2018/9698258 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2018 Mar 20;2018:9698258. doi: 10.1155/2018/9698258. 
      eCollection 2018.